’s () chairman Tim McCarthy caught up with Proactive London's Andrew Scott to discuss the results of a follow-up study which was designed to evaluate Lupuzor’s safety and tolerability.
McCarthy says the six month extension study confirmed its outstanding and robust safety profile.
He also details the subscription agreement with institutional investor, Lanstead Capital, which brought in around £2.66mln.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE